The Global "Helicobacter Pylori Diagnostics Market" is expected to grow at a high CAGR during the forecasting period (2022-2029).
Helicobacter pylori is a corkscrew-based bacteria that was identified in 1982 a significant cause of chronic gastritis and stomach ulcers.
These conditions are formerly believed to form by stress and poor diet. The symptoms of Helicobacter include stomach pain, bloating, tarry stools, and nausea. Blood, sweat, and breath are conventionally used to confirm the infection and followed by endoscopic examination for gatherer further insight into the disease.
It is also believed that Helicobacter pylori to be present in the upper part of the gastrointestinal tract of around 50% of the world population. Point of Care is one of the most common tests used to diagnose the infection.
An increase in the prevalence of Helicobacter pylori infection across the globe and awareness among the population regarding the disease is driving the global helicobacter pylori diagnostics market during the forecast period.
An increase in the prevalence of the geriatric population as they are prone to frequent gastrointestinal infections is additionally contributing to the growth of the Helicobacter pylori diagnostics market.
According to the recent news published by exalenz in February 2019, the prevalence of Helicobacter pylori bacteria in China is among the highest in the world underscoring the need for a highly accurate and easy administer test.
According to a study conducted by researchers at NEJM journal watch in March 2018, the overall prevalence of Helicobacter pylori infection was 44% and varied with geographical location.
Major Factors hindering the global helicobacter pylori market during the forecast period are the high cost associated with the equipment and the presence of undiagnosed patients.
Global helicobacter pylori diagnostics market is segmented by test type and end users, test type includes invasive and non-invasive testing, and end users include hospitals, clinics, diagnostic centers, public health labs, and others.
Invasive testing is sub-segmented to histology, rapid urea testing, an immunoassay, and non-invasive testing is sub-segmented to stool antigen test, serology test, and urea breath test.
Non-invasive testing is dominating the global helicobacter pylori diagnostics market during the forecast period owing to the higher adoption of non-invasive testing due to increased accuracy, precision, and the growing availability of testing facilities in hospitals and diagnostic laboratories.
The global helicobacter pylori diagnostics market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
North America dominates the global helicobacter pylori market during the forecast period owing to development in healthcare facilities and an increase in investment by government and non-government organizations for the development of new diagnostics devices.
An increase in the adoption of Helicobacter pylori eradication programs leading to demand diagnostic test products is additionally contributing to the global helicobacter pylori diagnostics market.
Africa is expected to grow at a higher CAGR during the forecast period owing to the increase in the prevalence of Helicobacter pylori infection across the region.
According to a study conducted by researchers at NEJM journal watch in March 2018, the incidence of Helicobacter pylori infection is highest in Nigeria with 87% of the global Helicobacter pylori infection population.
FDA approvals, new product launches by inducing current technological advancements in the test kits, and definite clinical trails attained by the key players in R&D of new diagnostic methodologies are driving the global helicobacter pylori diagnostics market during the forecast period.
On February 25th, 2019, Exalenz Bioscience receives approval for commercial marketing in China for its BreathID® Hp lab system.
On February 5th, 2019, Biomerica commenced the regulatory and clinical advancements in its development program for its H. pylori diagnostic product. It needs less than 40 clinical patient samples in addition to 210 samples already collected for final FDA clearance.
In October 2018, DiaSorin and Meridian made a Strategic Collaboration to Sell Diasorin FDA- cleared Helicobacter Pylori Stool Antigen Test in the United States and the United Kingdom.
In August 2018, Techlab received FDA 510(k) clearance for Helicobacter pylori Quick ChekTM and Helicobacter pylori chelTM Tests.
Major market players in the Helicobacter pylori diagnostics market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc, Quidel Corporation, Diasorin S.P.A, Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Abbott Laboratories, Halyard Health, Inc., Sekisui Diagnostics, Llc., and others.
Get your free sample proposal with a single click!